Electrocardiographic assessment for therapeutic proteins-scientific discussion

American Heart Journal

Volumn 160, Issue 4, 2010, Pages 627-634

  Rodriguez, Ignacio ^a   Erdman, Andrew ^b   Padhi, Desmond ^b   Garnett, Christine E ^c   Zhao, Hong ^c   Targum, Shari L ^c   Balakrishnan, Suchitra ^c   Strnadova, Colette ^d   Viner, Norman ^d   Geiger, Mary Jane ^e   Newton Cheh, Christopher ^f,g   Litwin, Jeffrey ^h   Pugsley, Michael K ⁱ   Sager, Philip T ^j   Krucoff, Mitchell W ^k   Finkle, John K ^l  

^a HOFFMANN LA ROCHE INC   (United States)

^b AMGEN INC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d HEALTH CANADA   (Canada)

^e ELI LILLY AND COMPANY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h ERT   (United States)

ⁱ JOHNSON AND JOHNSON   (United States)

^j Sager Consulting Partners   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIVALURIDIN; BLOOD CLOTTING FACTOR; BOTULINUM TOXIN; ERYTHROPOIETIN; FILGASTRIM; GEMTUZUMAB OZOGAMICIN; GROWTH HORMONE; HEPATITIS B SURFACE ANTIGEN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; INSULIN; INTERFERON; MONOCLONAL ANTIBODY; OXYTOCIN; RHESUS ANTIBODY; STREPTOKINASE; THYROTROPIN; TUBERCULIN; UNCLASSIFIED DRUG; VASOPRESSIN; WART VIRUS VACCINE; PROTEIN;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; GENE THERAPY; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; QT INTERVAL; QT PROLONGATION; REVIEW; RISK MANAGEMENT; ARRHYTHMIAS, CARDIAC; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ARRHYTHMIAS, CARDIAC; BIOMEDICAL RESEARCH; ELECTROCARDIOGRAPHY; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROTEINS;

EID: 77957830531     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.07.001     Document Type: Review

References (37)

1. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link J Intern Med 259 2006 59 69
2. Shah R.R. Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance Drug Saf 30 2007 1093 1110
3. ICH Expert Working Group ICH E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. International Conference on Harmonisation step 4 guideline, EMEA, CHMP/ICH/2/04. 2005 Available at: http://www.ich.org/LOB/media/MEDIA1476.pdf. Last accessed June 24, 2010
4. ICH Expert Working Group ICH S7B. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals International Conference on Harmonisation step 4 guideline, EMEA, CHMP/ICH/12/05 2005 Available at: http://www.ich.org/LOB/media/ MEDIA2192.pdf Last accessed June 24, 2010
5. Vargas H.M., Bass A.S., and Breidenbach A. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics J Pharmacol Toxicol Methods 58 2008 72 76
6. Leader B., Baca Q.J., and Golan D.E. Protein therapeutics: a summary and pharmacological classification Nat Rev Drug Discov 7 2008 21 39
7. Sanguinetti M.C., and Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia Nature 440 2006 463 469
8. Mitcheson J.S. hERG potassium channels and the structural basis of drug-induced arrhythmias Chem Res Toxicol 21 2008 1005 1010
9. Zhang M., Korolkova Y.V., and Liu J. BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1 Biophys J 84 2003 3022 3036
10. Wang J., Wang H., and Zhang Y. Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator J Biol Chem 279 2004 13289 13292
11. Gastaldelli A., Emdin M., and Conforti F. Insulin prolongs the QTc interval in humans Am J Physiol Regul Integr Comp Physiol 279 2000 R2022 R2025
12. Faigel D.O., Metz D.C., and Kochman M.L. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance Am J Gastroenterol 90 1995 822 824
13. Mauro V.F., Bingle J.F., and Ginn S.M. Torsade de pointes in a patient receiving intravenous vasopressin Crit Care Med 16 1988 200 201
14. Liou S.C., Chen C., and Wong S.Y. Ventricular tachycardia after oxytocin injection in patients with prolonged Q-T interval syndrome-report of two cases Acta Anaesthesiol Sin 36 1998 49 52
15. Charbit B., Funck-Brentano C., and Samain E. QT interval prolongation after oxytocin bolus during surgical induced abortion Clin Pharmacol Ther 76 2004 359 364
16. Shah M.H., Binkley P., and Chan K. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors Clin Cancer Res 12 2006 3997 4003
17. Yavas O., Yazici M., and Eren O. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients Swiss Med Wkly 137 2007 556 558
18. Ewer S.M., and Ewer M.S. Cardiotoxicity profile of trastuzumab Drug Saf 31 2008 459 467
19. Nakamura K., Katayama Y., and Kusano K.F. Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome J Am Coll Cardiol 50 2007 1808 1809
20. Curigliano G., Spitaleri G., and Fingert H.J. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development Eur J Cancer 44 2008 494 500
21. Sarapa N., and Britto M.R. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents Expert Opin Drug Saf 7 2008 305 318
22. Rock E.P., Finkle J., and Fingert H.J. Assessing proarrhythmic potential of drugs when optimal studies are infeasible Am Heart J 157 2009 827 836e1
23. Haller C., Cosenza M., and Sullivan J. Safety issues specific to clinical development of protein therapeutics Clin Pharmacol Ther 84 2008 624 627
24. Kurzrock R., and Benjamin R.S. Risks and benefits of phase 1 oncology trials, revisited N Engl J Med 352 2005 930 932 (Pubitemid 40300304)
25. Zhang J., and Machado G.S. Statistical issues including design and sample size calculation J Biopharm Statist 18 2008 451 467
26. Chtcheglova L.A. Localization of the ergtoxin-1 receptors on the voltage sensing domain of hERG K+ channel by AFM recognition imaging Pflugers Arch 456 2008 247 254
27. Lambert J.M. Drug-conjugated monoclonal antibodies for the treatment of cancer Curr Opin Pharmacol 5 2005 543 549
28. Reichert J.M. Monoclonal antibodies as innovative therapeutics Curr Pharm Biotechnol 9 2008 423 430
29. Garnett C.E., Beasley N., and Bhattaram V.A. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review J Clin Pharmacol 48 2008 13 18
30. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation AAPS J 7 2005 E609 624
31. Dayneka N.L., Garg V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses J Pharmacokinet Biopharm 21 1993 457 478
32. Sheiner L.B., Stanski D.R., and Vozeh S. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin Pharmacol Ther 25 1979 358 371
33. Gurbaxani B. Mathematical modeling as accounting: predicting the fate of serum proteins and therapeutic monoclonal antibodies Clin Immunol 122 2007 121 124
34. Strevel E.L., Ing D.J., and Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 2007 3362 3371
35. MedDRA MSSO Northrop Grumman Corporation Available at: http://www.meddramsso.com/index.asp Last accessed June 24, 2010
36. ICH Expert Working Group ICH E2E pharmacovigilance planning. International Conference on Harmonisation step 4 guideline, EMEA, CHMP/ICH/377/95 Available at: http://www.ich.org/LOB/media/MEDIA1195.pdf Last accessed June 24, 2010
37. FDA Development and use of risk minimization action plans. USHHS. FDA guidance documents Available at: http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM126830.pdf 2005 Last accessed June 24, 2010